AXIM Biotechnologies, Inc. (AXIM)

Market Cap	1.31M -26.1%
Revenue (ttm)	92.90K +257.9%
Net Income	-4.14M
EPS	-0.02
Shares Out	363.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,210
Open	0.0036
Previous Close	0.0040
Day's Range	0.0036 - 0.0037
52-Week Range	0.0020 - 0.0288
Beta	-0.08
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About AXIM Biotechnologies

AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXIM

Financial Performance

In 2023, AXIM Biotechnologies's revenue was $39,518, an increase of 345.27% compared to the previous year's $8,875. Losses were -$8.06 million, 29.1% more than in 2022.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 28, 2026

Data Sources Report a data error